PATIENTS’ QUALITY OF LIFE AND SIDE EFFECT PERCEPTIONS IN MONARCHE, A STUDY OF ABEMACICLIB PLUS ENDOCRINE THERAPY IN ADJUVANT TREATMENT OF HR+, HER2-, NODE-POSITIVE, HIGH-RISK, EARLY BREAST CANCER

THE PROGNOSTIC PERFORMANCE OF PREDICT+ IN PATIENTS (PTS) WITH HER2-POSITIVE (HER2+) EARLY-STAGE BREAST CANCER (EBC)

SURVIVAL OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS IN THE PRE-IMMUNOTHERAPY AGE. AN ANALYSIS OF GRUPPO ITALIANO MAMMELLA (GIM) 14 BIOMETA STUDY WITH A FOCUS ON BIOLOGICAL SUBTYPES

EFFICACY OF NIRAPARIB BY TIMING OF SURGERY AND RESIDUAL DISEASE: A POST HOC ANALYSIS OF PATIENTS IN THE PRIMA/ENGOT-OV26/GOG-3012 STUDY

NIVOLUMAB PLUS CABOZANTINIB (N+C) VS SUNITINIB (S) FOR ADVANCED RENAL CELL CARCINOMA (ARCC): OUTCOMES BY BASELINE DISEASE CHARACTERISTICS IN THE PHASE 3 CHECKMATE 9ER TRIAL

REAL-WORLD STUDY OF CABOZANTINIB IN PTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER VEGF-TARGETED THERAPY (CASSIOPE): INTERIM DATA FOR PATIENTS WHO HAD RECEIVED PRIOR NIVOLUMAB

CEMIPLIMAB MONOTHERAPY AS FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH BRAIN METASTASES (METS) FROM ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) >=50%; EMPOWER-LUNG 1 SUBGROUP ANALYSIS

5-YEAR OVERALL SURVIVAL (OS) IN COLUMBUS: A RANDOMIZED PHASE 3 TRIAL OF ENCORAFENIB PLUS BINIMETINIB VERSUS VEMURAFENIB OR ENCORAFENIB IN PATIENTS (PTS) WITH BRAF V600-MUTANT MELANOMA

OSTENONECROSIS OF THE JAW (ONJ) AFTER DENOSUMAB IN GIANT CELL TUMOR OF BONE (GCTB): A SINGLE INSTITUTION ANALYSIS OF PATIENTS WITH RESECTABLE AND UNRESECTABLE TUMORS ENROLLED IN A PROSPECTIVE, INTERNATIONAL STUDY 20062004